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Background: Overexpression of the Cut homeobox 1 gene, CUX1, inversely correlates with patient survival in breast
cancers. Cell-based assays and molecular studies have revealed that transcriptional regulation by CUX1 involves
mostly the proteolytically processed p110 isoform. As there is no antibody specific to p110 CUX1 only, an alternate
strategy must be employed to identify its targets.
Results: We expressed physiological levels of a tagged-p110 CUX1 protein and performed chromatin affinity
purification followed by hybridization on ENCODE and promoter arrays. Targets were validated by chromatin
immunoprecipitation and transcriptional regulation by CUX1 was analyzed in expression profiling and RT-qPCR
assays following CUX1 knockdown or p110 CUX1 overexpression. Approximately 47% and 14% of CUX1 binding
sites were respectively mapped less than 4 Kbp, or more than 40 Kbp, away from a transcription start site. More
genes exhibited changes in expression following CUX1 knockdown than p110 CUX1 overexpression. CUX1 directly
activated or repressed 7.4% and 8.4% of putative targets identified on the ENCODE and promoter arrays
respectively. This proportion increased to 11.2% for targets with 2 binding sites or more. Transcriptional repression
was observed in a slightly higher proportion of target genes. The CUX1 consensus binding motif, ATCRAT, was
found at 47.2% of the CUX1 binding sites, yet only 8.3% of the CUX1 consensus motifs present on the array were
bound in vivo. The presence of a consensus binding motif did not have an impact on whether a target gene was
repressed or activated. Interestingly, the distance between a binding site and a transcription start site did not
significantly reduced the ability of CUX1 to regulate a target gene. Moreover, CUX1 not only was able to regulate
the next adjacent gene, but also regulated the gene located beyond this one as well as the gene located further
away in the opposite direction.
Conclusion: Our results demonstrate that p110 CUX1 can activate or repress transcription when bound at a
distance and can regulate more than one gene on certain genomic loci.
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The last decade has seen significant advances in the field
of transcription. The discovery of nuclear histone
acetyltransferases (HATs) in the mid nineties has literally
opened a new field of investigation into post-translational
modifications that target histones and modulate the
chromatin state either locally or over large genomic loci.
The multiple types of modifications that take place on
specific histone residues and the regulatory cascades that
can be triggered in this manner led investigators to
propose that a "histone code" regulates gene expression in
a manner reminiscent of the genetic code translating
nucleic acid coding sequences into protein sequences
[1,2]. In parallel, a number of novel experimental
approaches have contributed to move the transcription
field from a gene-by-gene approach focused on core
promoters to a genome-wide non-biased approach that
enables us to study large numbers of transcriptional tar-
gets as well as the mechanisms by which these targets are
regulated [3]. Recent tools in our arsenal include the
increasing availability of genomic microarrays [4], siRNA-
mediated gene knockdown [5], more efficient virus-based
gene delivery systems [6,7], and high-throughput sequen-
cing [8]. Importantly, the "rediscovery" of chromatin
immunoprecipitation combined with the development of
microchip arrays containing large numbers of genomic
sequences has opened new horizons. Indeed, chromatin
immunoprecipitation was first described in the mid
eighties by the group of John T. Lis who used this assay to
show that RNA polymerase II molecules were already
present at the 5' end of the hsp70 gene in uninduced cells
and that heat shock somehow enabled transcription
elongation to take place [9]. Curiously, the method was
not applied to specific transcription factors before another
decade [10]. Interestingly, the genomic microarray that
was designed as part of the ENCODE project provided a
sampling of the human genome that can be interrogated
to define the distribution types of transcriptional regula-
tion of specific transcription factors [11]. The information
thus gathered has forced us to reconsider our original
understanding of basic mechanisms of transcriptional
regulation [12]. For example, a common belief was that a
specific transcription factor could bind to a few dozen
genes whose core promoters contain its consensus
binding site as defined in vitro, and once recruited to a
promoter could almost single-handedly regulate transcrip-
tion [13]. We now know that c-MYC binds to approxi-
mately 20% of gene promoters and is also capable of
regulating genes at a distance [14-16]. Another major
conceptual advance concerns the criteria to define a
transcriptional target. Experimental evidence typically
included the presence of a consensus binding motif within
a core promoter, in vitro binding assays and luciferase
reporter assays. While these assays are still employed, it isclear that they cannot provide definitive evidence that a
transcription factor regulates a specific gene. Additional
evidence must also include chromatin immunoprecipita-
tion assays to demonstrate "in vivo" DNA binding, and
change in expression of the endogenous gene target in
response to the knockdown and/or overexpression of the
transcription factor.
Cut homeobox 1 (CUX1) has previously been called
CCAAT-displacement protein (CDP), CDP/Cut and
Cut-like 1 (CUTL1). CUX1 encodes two main isoforms
that exhibit different DNA binding and transcriptional
properties (reviewed in [17]). The full-length protein,
p200 CUX1, is a very abundant protein that binds DNA
with extremely fast kinetics [18]. In mid-G1 phase, 1% to
10% of p200 CUX1 is proteolytically processed by a
nuclear isoform of cathepsin L to produce the p110 CUX1
isoform [19,20]. This shorter isoform can stably interact
with DNA and, depending on promoter-context, can
function as transcriptional repressor or activator [21,22].
The expression and activity of p110 CUX1 are tightly reg-
ulated in a cell cycle-dependent manner, mostly through
phosphorylation-dephosphorylation by cyclin A/Cdk2,
cyclin A/Cdk1 cyclin B/Cdk1, and Cdc25A, as well as pro-
teolytic processing by nuclear cathepsin L and a caspase-
like protease [19,20,23-27]. These post-translational
modifications circumscribe the transcriptional activity of
p110 CUX1 to the period between mid-G1 to sometimes
in G2. In contrast to p110 CUX1, the DNA binding
activity of p200 CUX1 is constant throughout the cell
cycle [19]. Its transcriptional activity, if any, would be
limited to the "CAATT-displacement activity", a mechan-
ism of passive repression involving competition for
binding site occupancy [18].
Homozygous inactivation of Cux1 in mice causes
perinatal lethality in a large proportion of animals due to
delayed lung development and associated respiratory
failure [28]. Surviving mice are usually male and exhibit
growth retardation, disrupted hair follicle morphogenesis,
purulent rhinitis, infertility, cachexia, and reduction of
B and T cell content in bone marrow and thymus, respect-
ively [28-30]. In transgenic mouse models, overexpression
of CUX1 generated various cancer-associated disorders
depending on the specific isoform and tissue type
expression. These include multi-organ organomegaly,
glomerulosclerosis and polycystic kidneys, pre-cancerous
lesions in the liver, myeloproliferative-disease-like myeloid
leukemias and mammary tumors sometimes associated
with lung metastasis [31-36]. Cell-based assays demon-
strated a role for CUX1 in cell cycle progression and cell
proliferation [27,37], strengthening of the spindle assem-
bly checkpoint [38], cell migration and invasion
[22,39-41], resistance to apoptotic signals [42], and
dendrite branching and spine development in cortical





























Figure 1 Expression of CUX1 Recombinant Proteins. (A) Schematic
representation of CUX1 proteins with some of the functional domains:
ID, inhibitory domain; CC, coiled-coil; CR1, CR2 and CR3, Cut repeat 1, 2
and 3; HD homeodomain; CBD, calmodulin binding domain; Prot A,
protein A. The regions recognized by the 861 and 1300 antibodies are
shown. (B) Hs578t cells were infected with a retroviral vector to
establish a population of cells stably expressing a recombinant p110
CUX1 protein with two tags at its C-terminus, p110 CUX1-Tag2.
A population stably carrying the empty vector was used as a control.
Nuclear extracts were prepared from each population of cells and
analyzed by Western blot using the 861 and 1300 CUX1 antibodies.
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shRNA-mediated knockdown approaches, however, in
overexpression studies the p110 CUX1 isoform was
shown to regulate transcription of genes involved in
cell cycle progression, DNA damage response, spindle
assembly checkpoint and cell motility.
Many specific transcription factors are able bind to
genomic sites that are far away from TSS. These studies
also revealed that only about up to 10% of putative
transcriptional targets showed evidence of regulation in
response to changes in transcription factor concentrations
[44-46]. Whether CUX1 binds preferentially to core
promoter sequences, like E2F1, or whether it can also bind
at a distance from TSS, like c-Myc, has not been
determined [14,15]. Also, what proportion of all CUX1
targets is regulated in response to overexpression or
silencing of CUX1 is not known. To begin to address
these questions, we have performed ChAP-chip using
ENCODE and promoter microarrays. Putative targets
were validated in independent ChIP followed by q-PCR,
while regulatory effects were measured in expression
profiling experiments and confirmed by RT-qPCR. The
results show that CUX1 binds to a large number of
genomic sites that are located far away from a TSS and
can regulate genes at a distance even when another gene
is located in the intervening region.
Results
Strategy to identify p110 CUX1 binding sites
The overall goal of the present study was to define the
modes of transcriptional regulation by CUX1 and, in
particular, determine whether CUX1 can regulate genes at
a distance. As detailed in the introduction, previous
transcriptional studies and cell-based assays have impli-
cated the p110 CUX1 isoform in transcriptional activation
and repression of target genes. Since p110 CUX1 is gener-
ated by proteolytic processing, its primary sequence is
included in the full-length CUX1 protein sequence.
Consequently, all available antibodies that bind to p110
CUX1 also recognize p200 CUX1. Our strategy to identify
in vivo binding sites for p110 CUX1 was to isolate
chromatin by two different methods. First, we purified
chromatin by tandem affinity purification (TAP) using a
population of Hs578t cells stably expressing moderate
levels of a p110 CUX1 protein with two epitope tags at its
C-terminus, p110-Tag2 (Figure 1A and B). Chromatin
isolated in this manner as well as total chromatin (input)
were used in hybridizations on the NimbleGen HG17
ENCODE high density oligonucleotide tiling array.
Secondly, binding sites identified in the microarray were
then validated by performing independent ChIP in the
parental Hs578t cells using CUX1 antibodies, 861 and
1300 (Figure 1A). Importantly, these cells express
endogenous CUX1 proteins only. The strategy ofchromatin affinity purification (ChAP) followed by micro-
array analysis (ChAP-chip) has previously been validated
[47], and described in detail [48].
Distribution of CUX1 binding sites on the ENCODE array
Using a stringent false discovery rate (FDR = 0.05),
513 CUX1 binding sites were identified on the ENCODE
array (Table 1). The recruitment of CUX1 to 23 out
of 25 genomic sites (92%) was validated in quantitative-
PCR assays using chromatin that was independently
obtained from Hs578t cells by immunoprecipitation
with CUX1 antibodies (Table 1). 79.6% of probes on
the ENCODE array derive from transcribed genomic
regions. 70.9% of CUX1 binding sites were located within
transcribed regions, indicating a 1.6-fold enrichment in
non-transcribed regions. In comparison, data obtained
from ChIP on the ENCODE platform [14] for c-MYC
reveals a 1.56 fold enrichment in non-transcribed regions
while E2F1 showed a strong enrichment for transcribed
regions (Table 2).
Table 1 CUX1 binding sites on the ENCODE array
# of binding sites 513
Average site width (bp) 503
Sites tested in qPCR 25
Validation rate 92%
Validation rate (with consensus) 100%
Validation rate (no consensus) 90%
Number and average width of CUX1 binding sites identified on the
NimbleGen HG17 ENCODE array using chromatin purified from Hs578t cells.
Also shown are the number and percentage of binding sites that were
validated in an independent ChIP experiment. The validation rate is also
shown independently for sites that contained the ATCRAT consensus
sequence as well as for sites that did not.
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start sites (TSS) generated a bell-shaped curve of low
height around TSS (Figure 2A). 14.2% of all binding sites
overlapped a TSS, and an additional 17% and 16% of
binding sites were respectively located in the 4 Kbp region
upstream and downstream of a TSS. The number of
binding sites gradually declined with increasing distance.
Yet, over 6% and 8% of binding sites were situated at more
than 40,000 bp upstream or downstream, respectively,
from the closest TSS. 53% of CUX1 binding sites are
located more than 4,000 bp away from a TSS and approxi-
mately 14% of all CUX1 binding sites are situated at more
than 40,000 bp from a TSS.
We compared the distribution of CUX1 binding sites
with those of 3 randomly generated sets of binding sites,
as well as those of c-Myc and E2F1 using the data of Bieda
et al., 2006 [14] (Figure 2B and C). We note that the
distributions of randomly generated sets of binding
sites exhibited flatter bell-shaped curves around TSS
(Additional file 1: Figure S1). We conclude that the higher
frequency of CUX1 binding sites close to TSS reflects the
preferential recruitment of CUX1 to promoter regions.
The same cannot be said regarding the binding sites that
are located at more than 40 Kbp from TSS, since the same
proportions of randomly generated binding sites were
located in these regions.
In contrast to CUX1 and c-Myc, the E2F1 transcription
factor was found to bind almost exclusively to the region
immediately adjacent to TSS. The preference of E2F1 toTable 2 Distribution of CUX1, Myc and E2F1 binding sites in t
Encode platform
Number of binding sites
Non-transcribed regions 20.4%
Transcribed regions 79.6%
Enrichment in un-transcribed regions
P Value
Number of CUX1, C-Myc and E2F1binding sites in transcribed and un-transcribed re
are calculated using a Fisher's exact test.core promoter regions led the authors to posit that E2F1
is recruited via protein interactions with components of
the general transcription machinery [14]. The wider
distribution of binding sites observed for CUX1 and
c-Myc is also observed for other transcription factors
[15,49,50] (Additional file 2: Figure S2A-C), while other
factors show a preference for TSS similarly to E2F1
(Additional file 2: Figure S2D-E). Yet other factors show
different patterns of binding, such as Pax8, which exhibits
preference for non-promoter CpG islands and a tendency
to bind in the 10–100 Kbp range rather than close to
the TSS of genes [51].
Binding of CUX1 to distant regulatory elements
We compared the location of CUX1 binding sites that are
more than 4 Kb from the nearest TSS to DNAse hyper-
sensitivity mappings and ChromHMM data in human
mammary epithelial cells from published datasets. DNAse
hypersensitivity sites have been used as markers of
regulatory DNA elements such as enhancers, silencers,
insulators and locus control regions [52-55]. ChromHMM
is a computational method that compiles data from
histone modification mappings and integrates them to
predict genomic elements such as enhancers [56]. This
analysis revealed that respectively 19.2% and 22.1% of
distantly located CUX1 binding sites are present within
1 kb of a DNAse hypersensitivity site and of an enhancer
predicted (Table 3). Both of these proportions are greater
than what is seen for randomly distributed binding sites.
However, there was no enrichment of CUX1 binding sites
in proximity of insulator elements (Table 3). These results
are in agreement with the notion that CUX1 can perform
some regulatory functions when binding at a distance
from transcription start sites.
Detection of CUX1 binding sites and consensus binding
motif on promoter arrays
Promoter microarrays are useful because they enable one
to interrogate easily over 30,000 gene promoters. A limita-
tion is that only a limited amount of promoter sequences
can be included for each gene, precluding the detection of
far away binding sites that could play a role in transcrip-







gions. Also indicated are the fold enrichment in transcribed regions. P Values
Table 3 A fraction of CUX1 binding sites locate close to
enhancer elements and DHS sites
Type CUX1 Random Fold difference P Value
DHS 19.2% 12.9% 1.49 0.0109
Enhancers 22.1% 15.2% 1.45 0.0100
Insulators 4.43% 4.40% 1.01 1.0000
Percentages of CUX1 binding sites located more than 4 Kbps away from a TSS
but within 1 Kbp of the indicated type of genomic element. Percentages are
shown for a set of randomly generated binding sites of the same size
distribution as CUX1. P Value is calculated using a Fisher's exact test. See
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Figure 2 Distribution of CUX1, C-Myc and E2F1 Binding Sites
Relative to Transcription Start Sites. (A) Percentage of CUX1
binding sites located at various distances from the closest
transcription start site. The "0" column indicates genes where the
CUX1 binding site overlaps the start site. (B) Location of C-Myc
binding sites as per A. (C) Location of E2F1 binding sites as per A.
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between 17.2% to 26.6% of CUX1 binding sites would be
identified on commercially available promoter arrays
(Table 4). However, since for many distant CUX1 binding
sites another binding site is also present close to thetranscription start site, we estimated that between 44.6%
to 58.5% of gene targets would be identified on distinct
promoter arrays (Table 5). In contrast, as E2F1 is targeted
to transcription start sites, between 80.4% to 85.8% of
E2F1 binding sites would be expected to be identified on a
promoter array.
We verified these predictions by performing a
ChAP-chip experiment using the Nimblegen promoter
microarray. Total chromatin (input) as well as purified
chromatin from Hs578t cells expressing p110 CUX1-Tag2
were used in hybridization on the promoter array
of NimbleGen. Using a stringent false discovery rate
(FDR = 0.05), 5828 CUX1 binding sites were identified on
4706 gene promoters (Table 6). The recruitment of CUX1
to 25 out of 25 genomic sites (100%) was validated in
quantitative-PCR assays using chromatin that was
independently obtained from Hs578t cells by immunopre-
cipitation with CUX1 antibodies (Table 6). The vast
majority of target genes (83.7%) contained only one CUX1
binding site, yet a sizable fraction contained 2 or more
binding sites (Table 6).
According to the predictions shown in Table 5, 44.6% of
CUX1 target genes should be identified on the promoter
array from Nimblegen. We calculated the proportion of
ENCODE genes with a CUX1 binding site that were also
identified as putative targets of CUX1 in the promoter
array. When we considered all 513 CUX1 binding sites
and 445 adjacent ENCODE genes, we found that 92 genes
(21%) were identified in the promoter array (Table 7, third
column). When we considered only the 85 ENCODE
genes that were regulated in response to changes in CUX1
levels (see below), we found that 27 genes (32%) were
identified as putative target of CUX1 in the promoter
array (Table 7, third column).
The CUX1 consensus binding site, ATCRAT (where
R = C or A), was found to be present at 47.2% of the 5828
bound genomic sites (Table 8). This frequency was judged
to be significant as the CUX1 consensus binding site was
found to be present in only 17.5% of 5828 randomly
chosen regions of equal size. Notably, the GC content
between bound and unbound regions is practically
identical, and thus cannot account for the difference
in binding site occurrence (Table 8). Yet, only 8.3%
Table 4 Binding sites and target genes predicted to be identified in promoter arrays
Platform Promoter array
boundaries
% of Binding sites predicted in promoter array
CUX1 C-Myc E2F1
Nimblegen −3.5 kb to + 0.75 kb 17.2% 26.8% 80.4%
Agilent −5.5 kb to + 2.5 kb 23.4% 34.3% 84.3%
Affymetrix −7.5 kb to + 2.45 kb 26.6% 34.9% 85.8%
Percentages of CUX1, C-Myc and E2F1 binding sites that were identified on the ENCODE array and that are located within the boundaries of promoters on various
promoter array platforms.
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array were bound in vivo. We conclude that the CUX1
consensus binding site plays a role in the recruitment of
CUX1 at specific genomic locations, but the presence of a
consensus site is not sufficient.Identification of binding motifs in genomic regions
bound by CUX1
We envisioned that interactions with other transcription
factors play an important role in recruiting CUX1 to
specific locations. In agreement with this notion, func-
tional analysis revealed distinct sets of cellular functions
among gene targets that contain an ATCRAT consensus
and those that do not (Tables 9 and 10). To further test
the possibility that CUX1 may interact with other factors,
we investigated the presence of binding motifs other than
that of CUX1 using the MEME suite of analysis tools
(meme.nbcr.net/). We first tested the reliability of the tool
by using it to find motifs in the sequences of CUX1 BS
in which we had independently determined that
they contained the established ATCRAT consensus. As
expected, it identified the ATCRAT consensus as the most
enriched motif in the set of sequences, by a vast margin
(Table 11, entry 1). We then analyzed binding motifs in
the two sets of CUX1 binding sites: those that contained
the ATCRAT motif and those that did not. While the size
of bound regions varied from 149 to 1107 bp, the average
size was 532 and 477 bp, respectively. Interestingly, only
one common binding motif was found in the two sets,
while the rest of the binding motifs were unique to each
set (Tables 11 and 12). Extending the search to the 500 bp
regions on either side of bound regions did not highlight
other differences between the two sets or reveal additional
contributing factors (Tables 13 and 14). These findings
support the notion that targeting of CUX1 to specificTable 5 Binding sites and target genes predicted to be identi
Platform Promoter array
boundaries CUX1
Nimblegen −3.5 kb to + 0.75 kb 44.6%
Agilent −5.5 kb to + 2.5 kb 57.1%
Affymetrix −7.5 kb to + 2.45 kb 58.5%
Percentages of CUX1, C-Myc and E2F1 target genes that are identified on the ENCO
promoters on various promoter array platforms.genomic sites is influenced by protein-protein interactions
with other DNA binding proteins.
Regulatory effects of CUX1 on putative targets
To verify the effect of CUX1 on putative targets, we
performed expression profiling on three Hs578t cell
populations: cells that had been infected with a retrovirus
expressing an shRNA against CUX1, cells infected with a
retrovirus expressing p110 CUX1, or cells infected with
an empty retrovirus. In each case, replicate microarray
hybridizations were carried out such that a p value could
be calculated for each difference in gene expression.
Results from expression profiling were validated by
repeating the infections and performing RT-qPCR analysis
on 20 genes whose expression went up or down in
response to one treatment or the other (Figure 3). All
genes tested in this manner displayed changes in gene
expression in the same direction as that observed in the
microarray hybridization: genes that were repressed in
expression profiling were also repressed when mRNA
levels were measured by RT-qPCR. Similar observations
were made for genes that were activated. We note,
however, that the fold activation or repression calculated
by RT-qPCR were not necessarily proportional to the
changes observed in microarray hybridization. For
example, EEF1A1 and C20ORF44 mRNA were increased
respectively 7.3 and 1.8 fold when measured by RT-qPCR,
but were increased 1.7 and 1.4 fold in microarray analyses.
Some of these differences could be due to the fact that
measurements by the two methods were made with RNA
prepared from independent experiments. Notwithstanding
the differences in magnitude, the effects of CUX1 on gene
expression was confirmed for all tested genes.
A total of 445 genes are present on the ENCODE array,
and all have a CUX1 binding site located within 213 Kbp
of their TSS. Expression profiling results could befied in promoter arrays





DE array and whose binding site are located within the boundaries of
Table 6 CUX1 binding sites on the promoter array
Genes on array 20593 Number of sites/gene Number of genes
CUX1 Binding sites 5828 1 3942
Genes bound by CUX1 4706 2 643
Average Site Width (bp) 503 3 90
Sites tested in qPCR 25 4 23
Validation rate 100% 5+ 8
Columns 1 and 2: Number and average width of CUX1 binding sites identified on the NimbleGen HG18 Human Promoter Array using chromatin purified from
Hs578t cells. Also shown are the number and percentage of binding sites that were validated in an independent ChIP experiment.
Columns 3 and 4: Number of genes with the indicated number of CUX1 binding site. Note that validation was performed on 14 and 11 sites that contained or not
an ATCRAT motif. All of them were validated.
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either up or down-regulated and a p value below 0.05, we
observed differences in the expression of 26 target genes
(7.4%), following changes in CUX1 levels (Table 15).
20 genes responded to CUX1 knockdown, and 6 genes,
to p110 CUX1 overexpression (Table 15). Among the
26 regulated target genes, 10 genes (38%) were activated
and 16 genes (62%) were repressed by CUX1 (Table 15).
Similar proportions of activated and repressed genes were
found when a cut-off of 25% change in gene expression
was employed (Table 16). These findings confirm that
p110 CUX1 can participate in transcriptional activation or
repression depending on promoter context.
Similar results were obtained when we analyzed the
expression of putative targets identified on the promoter
array. A total of 347 genes, 8.4% of all putative targets for
which expression profiling results could be matched, were
regulated by CUX1. 287 and 85 genes exhibited regulation
in response to CUX1 knockdown or p110 CUX1
overexpression, respectively. 181 (52%) were up-regulated
by CUX1 while 167 (48%) were down-regulated by CUX1.Effect of distance on transcriptional regulation by CUX1
We noted that CUX1 regulated 7.4% and 8.4% of putative
targets from the ENCODE and the promoter arrays,
respectively. We next investigated the relationship
between the position of a CUX1 binding site relative to a
transcription start site and the probability of a gene to be
regulated in response to changes in CUX1 levels. When
genes were classified according to the distance between
the CUX1 binding site and the transcription start site, we
did not observe significant difference in the fraction of
targets that were regulated by CUX1 (Figure 4A and B).Table 7 Binding sites and target genes predicted to be identi
Tot
All Genes on the ENCODE Array 44
Regulated Genes on the ENCODE Array (1.25) 85
Regulated Genes on the ENCODE Array (1.5) 26
The second column shows the number of genes on the ENCODE. The third column
on the Nimblegen promoter array.However, we observed much variability in the fraction of
regulated genes because the number of genes within some
distance intervals were very small. Therefore, to increase
the sample size, we repeated the analysis this time using a
cut-off of 25% either up or down and a p value below 0.05
(Figure 4C and D). We observed differences in the expres-
sion of 62 and 36 genes in response to CUX1 shRNA and
CUX1 overexpression, respectively (Table 16). Again,
more genes were found to be regulated by CUX1 using
the shRNA approach. Among genes that exhibited regula-
tion by CUX1, 35 genes (41%) were activated by CUX1,
and 50 genes (59%) were repressed by CUX1 (Table 16).
The histogram presenting the percentage of regulated
genes versus the distance of CUX1 binding sites to TSS
shows that essentially the same proportion of genes are
regulated whether CUX1 binds close or far away from the
TSS (Figure 4C). Indeed, no statistical difference was
observed between genes bound at the TSS and those
bound more than 40 Kbp away. We conclude that CUX1
can activate or repress transcription when bound at a
distance from a transcription start site.Effect of multiple CUX1 sites
The presence of multiple CUX1 binding sites has a
modest, yet significant, impact on the probability that a
gene is regulated by CUX1. CUX1 regulated 7.9%, 11.2%
of genes that contain respectively one or two CUX1
binding sites, respectively (Table 17).Effect of gene position on transcriptional regulation by CUX1
Intuitively, one would assume that a transcription factor
is more likely to regulate the closest promoter. Yet,
some enhancers will exhibit an effect on a promoterfied in promoter arrays




shown the number and percentage of these genes that were also identified
Table 8 CUX1 consensus binding sites and bound genomic regions
Regions Regions with consensus % with consensus GC Content
Bound Regions 5828 2749 47.2%*** 47.3%
Unbound Regions 5828 1020 17.5% 47.0%
Columns 2–4, occurrence of the CUX1 consensus binding site, ATCRAT (where R = C or A), within the 5828 genomic regions bound by CUX1 on the promoter
array. To calculate the p value, an equal number of randomly chosen regions of equal width was searched for the presence of the CUX1 consensus binding site:
***: p < 0.001. Column 5 shows the GC content of bound and unbound regions.
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is on the other side on the map. This sort of selectivity
between an enhancer and a promoter has been explained
by the presence of boundary or insulator elements or by
specific interactions between proteins bound at the
enhancer and the regulated promoter. Previous studies
on CUX1 have all focused on genes that contain a CUX1
binding site within the immediate promoter. To begin to
investigate the rules that govern the action of CUX1, we
calculated the fraction of different types of CUX1 targets
that were regulated in response to changes in CUX1
levels. Three types of genes were analyzed: 1, genes that
are the closest to the CUX1 binding site; 2, genes that are
further away and in the other direction from the CUX1
binding site; 3, genes that are located further away and are
separated by another gene from the CUX1 binding site.
For each category, we calculated the percentage of genes
that exhibit a 1.25 or 1.5-fold change in expression
following p110 CUX1 overexpression or CUX1 knock-
down. Strikingly, essentially similar fractions of genes
were regulated whether they were closest to the CUX1
binding site or were located further away in the other
direction (Figure 5, compare 1 and 2). Moreover, the
proportion of regulated genes was not significantly lower
among genes that belong to the third category (Figure 5,
type 3 genes). We conclude that CUX1 is capable ofTable 9 Functions of CUX1 target genes that contain a





Macromolecular complex assembly 1.39 3.1E-04
Microtubule cytoskeleton organization 1.88 6.1E-04
Cytoskeleton organization 1.47 6.6E-04
Response to DNA damage stimulus 1.51 7.2E-04




Cellular response to stress 1.38 1.4E-03
Cellular macromolecule catabolic process 1.32 1.5E-03
Protein localization 1.28 1.7E-03
Translational elongation 1.97 2.3E-03
Ten most over-represented biological functions of CUX1 targets gene from the
promoter array which contain a consensus CUX1 binding sequence (ATCRAT).
Overrepresentation is determined using the online DAVID tool.regulating genes at a distance. Moreover, CUX1 can
regulate more than one gene on certain genomic loci.
Discussion
Genome-wide location analysis on the ENCODE array
revealed that ~47% of CUX1 binding sites are located in
the 4-Kbp region upstream and downstream of a TSS,
while more than 14% of CUX1 binding sites are situated
at more than 40 Kbp from a TSS (Figure 2). Overall,
7.4% and 8.4% of putative targets on the ENCODE and
promoter arrays respectively, exhibited a 1.5-fold change
in expression following CUX1 knockdown or p110
CUX1 overexpression (Tables 15, 16, 17, 18 and 19).
This proportion is within the 1-10% range of potential
targets that have been reported to be regulated by other
transcription factors [44-46].
Importantly, analysis of the percentage of regulated
genes versus the distance of CUX1 binding sites to TSS
showed that essentially the same proportion of genes are
regulated whether CUX1 binds close or far away from the
TSS (Figure 4A and B). In other words, the probability that
a gene is regulated by CUX1 is not affected by the distance
between the CUX1 binding site and the TSS. In addition,
our results indicate that the position of genes relative to a
CUX1 binding site do not determine whether these genes
are regulated by CUX1. CUX1 regulated similar percent-
ages of genes whether they were closest to the CUX1 bind-
ing site or were located further away in the other directionTable 10 Functions of CUX1 target genes that do not
contain a consensus CUX1 Binding site
Functional term Fold enrichment P Value
Ribonucleoprotein complex biogenesis 2.11 3.3E-06
Translation 1.73 1.1E-05
RNA processing 1.55 1.1E-05
Cell cycle 1.41 5.4E-05
Mitotic cell cycle 1.62 6.1E-05
Ribosome biogenesis 2.17 7.4E-05
Nuclear mRNA splicing, via spliceosome 2.02 8.0E-05
Cell cycle process 1.45 1.9E-04
Establishment of protein localization 1.38 1.9E-04
Translational elongation 2.19 3.0E-04
Ten most over-represented biological functions of CUX1 target genes from the
promoter array which do not contain a consensus CUX1 binding sequence
(ATCRAT). Overrepresentation is determined using the online DAVID tool.
Table 11 Identification of DNA motifs in CUX1 binding sites with the ATCRAT consensus
Motif Reverse complement E-Value Transcription factors
ATCRAT ATYGAT 3.5E-735 Cux1, Pbx1
GGGYGGGR YCCCRCCC 4.8E-35 Klf4, Klf7, Sp1, Sp4, Zfp281, Zfp740, Egr1
AAATAHW WDTATTT 1.9E-27 -
CTBCCTS SAGGVAG 6.30E-26 Spi1, Stat3, Fev, Sfpi1
CWCCDCC GGHGGWG 6.60E-23 -
DRGGAAA TTTCCYH 6.20E-21 -
BSTGTGTG CACACASV 1.20E-20 -
RGAGAAR YTTCTCY 2.60E-14 -
ACRCWG CWGYGT 3.70E-14 -
RAAACAAA TTTGTTTY 1.90E-11 Sox11, Sox4, Foxd3, Foxi1
10 Most enriched DNA motifs found in CUX1 binding sites that contain the ATCRAT CUX1 consensus. The DNA sequences considered in this analysis correspond
to the entire regions bound by CUX1 as defined in the microarray. The size of bound regions varies from 149 to 1107 bp (95th percentile) and is 532 bp on
average. Proteins with DNA binding motifs highly similar to the motifs are listed in the rightmost column. K = G/T, M = A/C, R = A/G, Y = C/T, S = C/G, W = A/T,
B = C/G/T, V = A/C/G, H = A/C/T, D = A/G/T.
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a surprisingly high proportion (5.4%) of genes that
were separated from their binding site by another gene
(Figure 5). Altogether these results demonstrate that
CUX1 can regulate genes at a distance and can regulate
more than one gene on certain genomic loci.
The proportion of target genes that were found to be
activated or repressed by CUX1, respectively 52% and 48%
(Tables 18), is significantly different from what we
reported in previous studies on target genes involved in
cell cycle progression, cell motility, or the DNA damage
response [21,22,57]. In each case, a vast majority of genes
were found to be activated by p110 CUX1, whether we
performed siRNA-mediated knockdown or overexpression
of p110 CUX1. One factor that may explain this could be
the functional classes of genes that were studied previ-
ously. The functional class of “cell cycle” genes includes
mostly genes that stimulate cell cycle progression. Out of












10 Most enriched DNA motifs found in CUX1 binding sites that do not contain the
correspond to the entire regions bound by CUX1 as defined in the microarray. The
on average. Proteins with DNA binding motifs highly similar to the motifs are listedactivated and 2 were repressed by CUX1 (while only one
was not affected) [21]. One of the two repressed genes,
p21WAF1/CKI1, code for a CDK-inhibitor that blocks cell
cycle progression, while the other, CCNH, is involved in
transcription and DNA repair. All target genes that were
activated play a positive role in cell cycle progression.
Similarly, among 19 targets that play a role in DNA
damage response, 18 were activated and one was repressed
[57]. The repressed gene again was p21WAF1/CKI1. Overall,
these results are consistent with the notion that CUX1
establishes a transcriptional program that promotes cell
cycle progression and at the same time ensures the
maintenance of genetic integrity.
We employed two experimental approaches to examine
the transcriptional regulation of genes by CUX1. Expres-
sion profiling was performed following shRNA-mediated
knockdown of CUX1 or p110 CUX1 overexpression.
Among targets identified on the promoter array,
287 genes exhibited a 1.5-fold change in expressionithout the ATCRAT consensus
E-Value Transcription factors
3.80E-35 -
4.60E-34 Klf4, Klf7, Sp1, Sp4, Zfp281, Zfp740, Egr1
1.50E-26 Gabpa, Stat1
3.20E-23 Runx1






ATCRAT CUX1 consensus. The DNA sequences considered in this analysis
size of bound regions varies from 149 to 949 bp (95th percentile) and is 477 bp
in the rightmost column.
Table 13 Identification of DNA motifs close to CUX1 binding sites with the ATCRAT consensus
Entry Motif Reverse complement E-value Match in Table 14 Factors
1 CNGCCTCC GGAGGCNG 2.9E-168 Entry 3 -
2 CTGTARTC GAYTACAG 2.5E-161 Entry 1 -
3 CAGGCTGG CCAGCCTG 3.7E-145 - -
4 AAAWAMAA TTKTWTTT 6.1E-135 Entry 2 Srf, Elf3, Tcfap2e
5 TGCAGTGR YCACTGCA 4.6E-115 Entry 6 Zbtb3
6 CCAGCTAC GTAGCTGG 8.9E-109 Entry 4 -
7 GAGACRGR YCYGTCTC 1.6E-108 - -
8 BGYGGTGG CCACCRCV 2.6E-92 - -
9 CTCCYGMC GKCRGGAG 1.7E-86 Entry 5 -
10 CAAAGTGC GCACTTTG 2.1E-71 Entry 10 -
10 Most enriched DNA motifs found within the 500 bp regions on either side of CUX1 binding sites that contain the ATCRAT CUX1 consensus. Column 5 lists
Table 14 entries whose motifs are very similar (max. 1 mismatch). Proteins with DNA binding motifs highly similar to the motifs are listed in the rightmost column.
K = G/T, M = A/C, R = A/G, Y = C/T, S = C/G, W = A/T, B = C/G/T, V = A/C/G, H = A/C/T, D = A/G/T.
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regulated in response to p110 CUX1 overexpression.
Therefore, more genes were found to be regulated by
CUX1 using the shRNA approach. This result can be
interpreted to mean that CUX1 is required for optimal
expression of many target genes, however, increasing
CUX1 expression is not sufficient to modulate the
expression of some target genes.
The CUX1 consensus binding site, ATCRAT (where
R = C or A), was found to be present at 47.2% of the
5828 bound genomic sites (Table 8). We conclude that the
presence of a CUX1 consensus binding site contributes to,
but is not sufficient for, the recruitment of CUX1 to
specific genomic locations. We envision that interactions
with other transcription factors play an important role in
recruiting CUX1 to specific locations. In agreement with
this notion, functional analysis revealed distinct sets of
cellular functions among gene targets that contain an
ATCRAT consensus and those that do not (Tables 9 and
10). We note that functional classes involved in cell cycleTable 14 Identification of DNA motifs close to CUX1 binding











10 Most enriched DNA motifs found within the 500 bp regions on either side of CU
lists Table 13 entries whose motifs are very similar (max. 1 mismatch). Proteins with
rightmost column.were over-represented among target genes that do not
contain a consensus CUX1 binding site (Table 10). In
previous studies, CUX1 was shown to interact with E2F
factors and cooperate with these factors in the regulation
of several cell cycle genes [58,59]. It is likely that protein-
protein interaction with E2F factors reduces the
requirement for the presence of a high-affinity binding site
for the recruitment of CUX1 on this class of genes.
CUX1 can be purified efficiently by immunoprecipita-
tion or affinity chromatography. Following cross-linking,
however, the yield of purification is drastically reduced
such that we need 500 million cells to perform
chromatin immunoprecipitation or affinity purification
(ChIP or ChAP) for CUX1. This caveat has limited our
ability to perform ChIP-sequencing and therefore our
study relied on microarray hybridizations. While sequence
coverage is admittedly smaller on microarrays, data
collected from both ENCODE and promoter arrays have
enabled us to define the importance of the CUX1
consensus binding site in the recruitment of CUX1 tosites without the ATCRAT consensus
E-Value Match in Table 13 Factors
3.9E-170 Entry 2 -
6.6E-170 Entry 4 Srf, Elf3, Tcfap2e
1.7E-160 Entry 1 -
6.2E-120 Entry 6 -
2.3E-116 Entry 9 -
2.6E-109 Entry 5 Zbtb3
1.4E-104 - Klf4, Klf7, Sp1, Sp4
2.4E-93 - Pdx1
2.0E-90 - -
2.0E-75 Entry 10 -
X1 binding sites that do not contain the ATCRAT CUX1 Consensus. Column 5























































































































































































































































Figure 3 Overexpression and Knockdown of CUX1 and Expression Profiling Validation. (A) Hs578t cells were infected with a lentiviral vector
expressing p110 CUX1 or nothing (vector). RNA and proteins were purified 48 hours post-infection. CUX1 expression was analyzed by RT-qPCR and
immunoblotting. (B) Hs578t cells were infected with a lentiviral vector expressing CUX1 shRNA or a scrambled RNA. RNA and proteins were purified 5
days after infection. CUX1 expression was analyzed by and RT-qPCR and immunoblotting. (C) RNA levels of the indicated genes were measured by
RT-qPCR in cells treated as in A. Expected up or down indicates regulation that was observed by expression profiling. (D) RNA levels of the indicated
genes were measured by RT-qPCR in cells treated as in B. Expected up or down indicates regulation that was observed by expression profiling. * p<0.05,
*** p<0.001 on a Student's T test.
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regulate genes at a distance.Conclusions
Our results demonstrate that p110 CUX1 can mediate
transcriptional repression or activation of specific genes
when bound at variable distances from the transcription
start site. Although the CUX1 consensus binding motif,
ATCRAT, plays a role in the recruitment of CUX1 toTable 15 Genes on the ENCODE array regulated in response t
Effect of CUX1 on 327 putative target genes CUX1 Overexpressio
Up- or Downregulated 26 (7.4
Upregulated 10 (2.9
Downregulated 16 (4.6
Number and percentage of genes on the ENCODE platform that exhibit a 1.5 fold c
"Upregulated by CUX1" are genes whose expression is increased following p110 CU
by CUX1" are genes whose expression is decreased following p110 CUX1 and/or incspecific genomic sites, protein-protein interactions must
contribute to its transcriptional activity.
Methods
Cell culture
Hs578T is a human mammary carcinoma cell line
[60]. Previous studies have documented changes in
gene expression in response both to CUX1 knockdown
and overexpression [21,33]. Hs578T cells were
maintained in Dulbecco’s modified minimum essentialo CUX1 overexpression or CUX1 knockdown (1.5 fold)
n or Knockdown CUX1 Overexpression CUX1 Knockdown
%) 6 (1.7%) 20 (5.7%)
%) 3 (0.9%) 7 (2.0%)
%) 3 (0.9%) 13 (3.7%)
hange in expression following p110 CUX1 overexpression or CUX1 knockdown.
X1 and/or decreased following CUX1 knockdown. Conversely, "Downregulated
reased following CUX1 knockdown.
Table 16 Genes on the ENCODE array regulated in response to CUX1 overexpression or CUX1 knockdown (1.25 fold)
Effect of CUX1 on 327 putative target genes CUX1 Overexpression or Knockdown CUX1 Overexpression CUX1 Knockdown
Up- or Downregulated 85 (24.4%) 36 (10.3%) 62 (17.8%)
Upregulated 35 (10.0%) 18 (5.2%) 24 (10.9%)
Downregulated 50 (14.3%) 18 (5.2%) 38 (6.9%)
Number and percentage of target genes on the ENCODE platform that exhibit a 1.25 fold change in expression following p110 CUX1 overexpression or CUX1
knockdown. Genes were analyzed as in Table 15.
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streptomycin, and 5% fetal bovine serum (FBS) (Gibco).
Retroviral infection and stable cell lines
Retroviruses were produced by transfecting 293VSV cells
with the pREV/TRE vector either empty or encoding
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Distance of CUX1 from TSS (bp)
Figure 4 Effect of Distance on Regulation by CUX1. (A) Genes from the
between their transcription start site (TSS) and the closest CUX1 binding sit
overlaps the start site. The histogram shows, for each interval of distance, t
following p110 CUX1 overexpression or CUX1 knockdown. The total numb
(B) As in A, except that the regulation by CUX1 is expressed as either activ
of 1.25 fold change in expression. (D) As in B, but with a threshold of 1.25and CBP tags inserted at the C-terminus) (Clontech).
Preparation of the retroviruses and stable cell lines was
done as previously described [37].
Chromatin Affinity Purification (ChAP)
The method of chromatin affinity purification (ChAP) has
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Distance of CUX1 from TSS (bp)
ENCODE array have been organized according to the distance
e. The "0" column indicates genes where the CUX1 binding site
he percentage of genes that exhibit a 1.5 fold change in expression
er of genes within each interval is indicated within each column.
ation by CUX1 or repression by CUX1. (C) As in A, but with a threshold
fold change in expression.
Table 17 Number of genes on the promoter array that are regulated in response to CUX1 overexpression or CUX1
knockdown
Number of sites/target Number of targets Targets with profiling data 1.5 fold change 1.25 fold change
Any # 4706 4140 347 8.4% 1437 34.7%
1 3942 3527 278 7.9% 1182 33.5%
2+ 643 613 **69 11.2% ***255 41.6%
Effect of the number of CUX1 binding sites on the probability that target genes exhibit a change in expression following p110 CUX1 overexpression or CUX1
knockdown, depending on the number of CUX1 binding site present in their promoter region. **: P < 0.01, ***:P < 0.001 on a Fisher's exact test vs. genes whose
promoter have only 1 CUX1 binding site.
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be expressed at moderate level, we employed the pRevTRE
retroviral vector (Clontech), which contains the minimal
CMV promoter with a tetracycline responsive element.
Importantly, no tetracycline was added to the medium.
Moreover, the Hs578T breast tumor cells do not express a
tetracycline-responsive transactivator. Basal expression
from the pRevTRE vector was previously shown to be very
low [61-63]. ChAP was performed on 5 x108 Hs578T. The
cell nuclei were purified as described in [64], then lysed in
RIPA-M buffer (10 mM Tris–HCl pH8, 1 mM EDTA,
0.5 mM EGTA, 150 mM NaCl, 1% Triton X-100,
0.5% DOC, 0.1% SDS, 1 mM PMSF, protease inhibitors)
and sonicated on ice to obtain 250- to 800-bp-long DNA
fragments. Stably expressed recombinant p110-Tag2 protein
was purified by the Taptag purification method with some
modifications [65]. The IgG matrix bound p110-Tag2/DNA
were washed in wash buffer I (20 mM Tris–HCl pH8,
2 mM EDTA, 2 mM EGTA, 150 mM NaCl, 1% NP-40,
0.5% DOC, 0.2% SDS), wash buffer II (20 mM Tris–HCl
pH9, 2 mM EDTA, 2 mM EGTA, 500 mM NaCl, 1%











Figure 5 Relationship Between Gene Position and Regulation
by CUX1. Three types of situations are depicted in the diagram. 1,
genes that are the closest to the CUX1 binding site; 2, genes that
are further away and in the other direction from the CUX1 binding
site; 3, genes that are located further away and are separated by
another gene from the CUX1 binding site. For each category, the
table shows the percentage of genes that exhibit a 1.25 or 1.5
change in expression following p110 CUX1 overexpression or
CUX1 knockdown.Tris–HCl pH7.5, 2 mM EDTA, 1 mM EGTA, 0.5 M LiCl,
1% NP-40, 0.7% DOC,) and then TEV buffer (10 mM
Tris–HCl (pH8.0), 100mMNaCl, 0.1% TX-100, 0.5 mM
EDTA, 10% glycerol, 1 mM DTT). After TEV protease
digestion, the released protein/DNA complexes were
purified by affinity chromatography on calmodulin beads in
the presence of calcium and then eluted with EGTA. After
de-crosslinking, samples were treated with RNase A and
Proteinase K. Un-enriched input chromatin was put aside
as a control.
Preparation of ChAP purified DNA for hybridization
ChAP purified chromatin was amplified by the method
of Ligation-Mediated PCR as detailed previously [66].
Briefly, ChAPed DNAs and input DNA were blunted,
ligated to a unidirectional linker and amplified by PCR
for 24 cycles to generate a sufficient amount of DNA.
Amplified DNA samples were Cy5 labeled and amplified
input controls were Cy3 labeled using Nimblegen's Dual-
Color DNA Labeling Kit according to the manufacturer's
instructions.
DNA microarray hybridization
Labeled samples were hybridized to either NimbleGen's
HG17 ENCODE or their HG18 Human Promoter Array
Set high density oligonucleotide tiling array (385 k probe
format) and then washed according to the manufacturer's
instructions. Arrays were scanned on an Agilent 5 μm
scanner model G2505B using customized scan area
settings (X: 28, Y:6, Width: 20, Height: 14, values in mm).
ChAP-microarray result analysis
For both array platforms (Encode and promoter array),
grid alignment, raw signal extraction, peak identification
and peak mapping were carried out using the Nimblescan
v8.0 software according to the company's instructions.
Identified peaks were considered significant with a false
discovery rate (FDR) below 0.05, which is considered
highly confident. Further analysis of identified binding
sites was carried our using either the R platform
for statistical computing (http://www.R-project.org) or
scripts written in PERL (Practical Extraction and Report
Language, www.perl.org). All peaks identified in ChAP-
Chip experiments on the Encode Array and the Human
Table 18 Number of genes on the promoter array that are regulated in response to CUX1 overexpression or CUX1
knockdown (1.25 fold)
Effect of CUX1 on all genes and 4140 putative targets CUX1 Overexpression or Knockdown CUX1 Overexpression CUX1 Knockdown
Gene list All genes Target genes Target genes Target genes
Up- or Downregulated 4880 27.7% 1437 34.7% 568 13.7% 1083 26.1%
Upregulated 2290 13.0% 696 16.8% 261 6.3% 546 13.2%
Downregulated 2590 14.7% 744 17.9% 307 7.4% 537 13.0%
Number and percentage of all genes and CUX1 target genes on the promoter array that exhibit a 1.25 fold change in expression following p110 CUX1
overexpression or CUX1 knockdown. Genes were analyzed as in Table 15.
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and 4, respectively).
ChAP-microarray result validation
Independent ChIP experiments using antibodies specific
for endogenous CUX1 were carried out in Hs578t, as
previously described [21]. Real-time PCR was used to
measure the level of enrichment of genomic target
regions in ChIP DNA vs. the un-enriched input DNA.
We selected 25 genes from both the targets identified on
the ENCODE array and on the Promoter array set and
designed primers specific for the corresponding regions
where CUX1 was putatively identified as binding.
ENCODE binding sites for c-MYC and E2F1
We used ChIP-chip binding sites for E2F1 and
c-Myc downloaded from the website of Dr. Peggy
Farnham laboratory at <http://genomics.ucdavis.edu/
farnham/suppdata.html>. This dataset contains the bind-
ing sites predicted for E2F1, c-MYC and POLR2A
(RNA polymerase II) in the ENCODE regions classified by
4 criteria: L1 (P < 0.0001 and 98th percentile), L2
(P < 0.0001 and 95th percentile), L3 (P < 0.05 and 98th
percentile) and L4 (P < 0.05 and 95th percentile) [14].
Based on the validation of 29 binding sites, Bieda et al.
conclude that L1 binding sites are highly reliable, L2 and
L3 binding sites are also reliable however based on sparser
testing and L4 binding sites are usually artifacts. Binding
sites identified with the L1 criteria were used for our
analyses. The chromosomal intervals for binding sites
predicted for E2F1 and POLR2A belonged to genomic
coordinates using hg16, whereas c-MYC binding sitesTable 19 Number of genes on the promoter array that are re
knockdown (1.5 fold)
Effect of CUX1 on all genes and 4140 putative targets CUX1 Overexp
Gene list All genes
Up- or Downregulated 1231 7.0
Upregulated 591 3.4
Downregulated 640 3.6
Number and percentage of all genes and CUX1 target genes on the promoter array
overexpression or CUX1 knockdown. "Upregulated by CUX1" are genes whose expr
knockdown. Conversely, "Downregulated by CUX1" are genes whose expression is d
The total number of genes and target genes were 17586 and 4140, respectively.were in hg17. Therefore, the lift-over program found on
the online GALAXY platform [67-69] was used and
random results were verified using UCSC genome browser
to convert hg16 coordinates to those of hg17. There were
1 and 2 binding sites for E2F1 at L1 and L3 respectively
(hg16), which could not be mapped to hg17.
DHS and ChromHMM data analysis
Data tracks were downloaded from the UCSC's Encode
data portal (http://genome.ucsc.edu/ENCODE/). Genomic
locations were compared to those of the CUX1 binding
sites using scripts written in R. UCSC Accession numbers
of the tracks used are: wgEncodeEH000503 (GEO
accessions GSM736552 and GSM736634) for the DHS data
and wgEncodeEH000786 for the ChromHMM data.
Consensus sequence analysis
Genomic sequences corresponding to regions of interest
(binding sites or other) were obtained using the online
GALAXY platform. Scripts written in R were used to
identify the ATCRAT consensus motif within regions of
interest.
De novo binding motif identification
De Novo motif discovery was performed using the
DREME (Discriminative DNA Motif Discovery) motif
discovery tools form the MEME suite of tools. Compari-
son with known DNA binding motifs was performed using
the TOMTOM algorithm using the JASPAR CORE data-
base as a reference for comparison. (meme.nbcr.net/)
[70-72].gulated in response to CUX1 overexpression or CUX1
ression or Knockdown CUX1 Overexpression CUX1 Knockdown
Target genes Target genes Target genes
% 347 8.4% 85 2.1% 287 6.9%
% 181 4.4% 28 0.7% 169 4.1%
% 167 4.0% 57 1.4% 118 2.8%
that exhibit a 1.5 fold change in expression following p110 CUX1
ession is increased following p110 CUX1 and/or decreased following CUX1
ecreased following p110 CUX1 and/or increased following CUX1 knockdown.
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Identification of overrepresented gene functions was
carried out using the online annotation tool DAVID.
Genes that were bound by CUX1 (Targets) were
compared with all genes present on the microarray
(Background). Overrepresentation of a function depends
on the increase in the proportion of genes involved in a
given function between CUX1 targets and the
background. The P-value is determined using an improved
Fisher’s exact test from the DAVID software [73,74].
p110 CUX1 overexpression and CUX1 shRNA
For overexpression, Hs578t cells were infected with a
lentiviral vector expressing p110 CUX1. Duplicate
infections were carried out in parallel and cells were
harvested after 24 hours. For CUX1 knockdown, a stable
Hs578t cell line containing a doxycycline inducible shRNA
was established by retroviral infection. Doxycycline was
applied to the cells for 6 days before harvest with control
cells left untreated. Knockdown experiments were carried
out in biological duplicates in parallel.
Expression profiling sample preparation and
hybridization
Total RNA was isolated from cells using the Arcturus
Picopure RNA isolation kit. 2 μg of RNA was then
amplified using the Arcturus RiboAmp PLUS RNA ampli-
fication kit according to the manufacturer's instructions
for a single round of amplification. Amplified mRNA
(aRNA) was labeled using the Arcturus Turbo Labelling
Cy5 and Cy3 kits using the manufacturer's instructions
with a modification: The labeling reaction was carried out
using 5 μg of aRNA in a 20 μl volume instead of 50 μl to
increase the dye incorporation rate. Labelled aRNA was
hybridized to Agilent's Whole Human Genome Microarry
(G4112F) according to the manufacturer's instructions,
washed and scanned on a 5 μm Agilent scanner.
Hybridizations of the biological duplicates of each experi-
ment were carried out in technical duplicates using dye
swaps (Cy3 and Cy5), for a total of 4 replicates for each of
the overexpression and downregulation experiment.
Expression profiling data analysis
Raw signal and background intensities were extracted
from the scanned images of expression arrays using the
Feature Extraction software from Agilent. Raw data was
processed and normalized using the R platform and the
LIMMA package [75]. Processed expression profiling
results are provided (Additional file 5).
Expression profiling result validation
Independent p110 CUX1 overexpression and CUX1
shRNA knockdown experiments were carried out in
Hs578t cells using retroviral vectors. 10 genes wereselected from each experiment and real-time PCR was
used to confirm the changes in expression seen in
expression profiling.
Additional files
Additional file 1: Figure S1. Distribution of 3 random sets of binding
sites relative to transcription start sites.
Additional file 2: Figure S2. Distribution of binding sites relative to
transcription start sites for 6 transcription factors.
Additional file 3: CUX1 Binding site peaks from ENCODE array
ChAP.
Additional file 4: CUX1 Binding site peaks from Promoter array ChAP.
Additional file 5: Expression profiling results following
overexpression and knockdown of CUX1.
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